Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZD-4190 是血管内皮细胞生长因子受体 2 (VEGFR2) 和表皮生长因子受体 (EGFR) 信号传导的抑制剂,用于治疗癌症。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 689 | 现货 | ||
2 mg | ¥ 1,050 | 现货 | ||
5 mg | ¥ 1,820 | 现货 | ||
10 mg | ¥ 2,730 | 现货 | ||
25 mg | ¥ 4,360 | 现货 | ||
50 mg | ¥ 5,930 | 现货 | ||
100 mg | ¥ 8,190 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,830 | 现货 |
产品描述 | ZD-4190 is a compound that inhibits both the vascular endothelial growth factor receptor 2 (VEGFR2) and the epidermal growth factor receptor (EGFR) signaling pathways, utilized in cancer treatment. |
体外活性 | ZD4190 can prevent outgrowth of malignant cells when the tumour burden is below a critical threshold. |
体内活性 | ZD4190 (100 mg/kg, p.o.) effectively delays MDA-MB-435 tumor growth in mice. In ZD4190-treated tumors, 18F-FPPRGD2 uptake has decreased significantly relative to baseline by 26.74 8.12% (p<0.05) on day 1 and by 41.19 6.63% (p<0.01) on day 3, then has returned to baseline on day 7. Tumor uptake of 18F-FLT has also decreased on both day 1 and day 3 after initiation of ZD4190 treatment. However, ZD4190 does not significantly change 18F-FDG uptake in tumors, compared with the control group. |
动物实验 | ZD4190 was administered by gavage suspended in 1% polysorbate 80 at 50 mg/kg 24 h after tumour cell implantation for a maximum of 22 days. Control rodents were gavaged with the vehicle only and a third group was untreated. In preliminary experiments, rodents were killed on alternate days so that the effect of ZD4190 on tumour outgrowth could be assessed and subsequently the treatment response was evaluated at day 9 or 22. At least five rodents were included in each treatment group. |
分子量 | 459.27 |
分子式 | C19H16BrFN6O2 |
CAS No. | 413599-62-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20.83 mg/mL (45.35 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1774 mL | 10.8868 mL | 21.7737 mL | 54.4342 mL |
5 mM | 0.4355 mL | 2.1774 mL | 4.3547 mL | 10.8868 mL | |
10 mM | 0.2177 mL | 1.0887 mL | 2.1774 mL | 5.4434 mL | |
20 mM | 0.1089 mL | 0.5443 mL | 1.0887 mL | 2.7217 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ZD-4190 413599-62-9 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR VEGFR Inhibitor inhibit Vascular endothelial growth factor receptor Epidermal growth factor receptor ErbB-1 ZD4190 HER1 ZD 4190 inhibitor